Clinical trial
Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara…
NCT00386633 · Bavarian Nordic, Industry · Completed
Key facts
| NCT number | NCT00386633 |
|---|---|
| Title | Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection |
| Official title | Phase I, Open, Sequential Vaccination Study on Safety and Tolerability of Two Different Doses of a Recombinant MVA HIV Polytope Vaccine (MVA-mBN32) in HIV-negative 18-50 Year Old Healthy Volunteers |
| Lead sponsor | Bavarian Nordic, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Biological |
| Interventions | MVA-mBN32 |
| Enrollment | 36 |
| Start date | Oct 1, 2006 |
| Completion | Nov 1, 2007 |
| First posted | Oct 11, 2006 |
| Last update posted | Jan 27, 2015 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: